The European Union Reference Laboratory (EU-RL) has produced guidelines for a real-time PCR for the detection of verocytotoxigenic Escherichia coli (VTEC). In this study, we validated the EU-RL assay on 545 strains of VTEC and evaluated the utility of the assay for the detection of VTEC from stool specimens. The validation study on cultures showed that the EU-RL VTEC PCR was 99.3% sensitive for the detection of vtx genes; only strains harbouring vtx2f genes were not detected. The assay was 100% sensitive and 100% specific for the detection of both the eae and O157 rfbE genes. In a prospective study involving 500 stool samples, the EU-RL VTEC PCR detected vtx genes in 12.4% of specimens, compared to 3.8% specimens found to be culturepositive for E. coli O157 using the Health Protection Agency national standard culture method. This study showed that the EU-RL VTEC assay was reliable and robust, and an effective rapid screening method for the detection of VTEC from stool specimens.
INTRODUCTION
The Laboratory of Gastrointestinal Pathogens (LGP) at the Health Protection Agency (HPA) in Colindale, London, UK, is the reference laboratory for confirmation of verocytotoxigenic Escherichia coli (VTEC) isolates from humans in England and Wales. Presumptive cultures of VTEC O157, submitted by diagnostic laboratories, are tested for verocytotoxin-encoding (vtx) genes by PCR; biochemical tests and serology identify isolates as E. coli and confirm their serotype (Gross & Rowe, 1985) . This process has resulted in confirmation of between 793 and 1034 human isolates of VTEC O157 annually in England and Wales over the period 2005-2010 (http://www.hpa.org.uk/webc/HPAwebFile/HPA web_C/1279889257510).
About 90% of approximately 3000 cultures presumptively identified in clinical laboratories and then submitted to the LGP between 2007 and 2009 were confirmed as VTEC or VTEC O157.
Block-based PCR testing for vtx genes has been reliable and robust, particularly for presumptive VTEC O157. However, as a result of increased workload and the need to screen colonies during diagnostic testing of faeces, a more rapid, cost-effective method with reduced risk of contamination that is less labour intensive is required. The European Union Reference Laboratory (EU-RL) for E. coli has produced guidelines for a real-time PCR that detects the vtx1 and vtx2 genes encoding the two major toxin types of VTEC, the intimin (eae) gene, which encodes a protein involved in the intimate attachment of E. coli to the gut mucosa and is found in strains causing serious illness, and the rfbE gene encoding the lipopolysaccharide O antigen of VTEC O157 (Nielsen & Andersen, 2003; Perelle et al., 2004; Kagkli et al., 2011) .
Because of phenotypic diversity, there are no simple, generally applicable culture-based tests for the detection of VTEC other than serogroup O157 (non-O157 VTEC) in faecal specimens. The HPA National Standard Methods (http://www.hpa-standardmethods.org.uk/) that are widely used in clinical microbiology laboratories in England and Wales for diagnosis and identification of E. coli O157 are not effective for the detection of VTEC generally. A small number (,15) of isolates of non-O157 VTEC are identified annually in England and Wales by diagnostic testing in the LGP using a combination of PCR and culture of faeces from cases of haemolytic uraemic syndrome (HUS) and bloody diarrhoea but their true incidence is unknown. In other countries, non-O157 VTEC has been identified as a significant cause of infectious intestinal disease, including HUS (Tozzi et al., 2003; Mellmann et al., 2008) , and its incidence has been found to exceed that of VTEC O157. This may reflect both actual prevalence and differences in testing methods. Studies using a real-time PCR-based approach for the detection of VTEC from stool specimens would facilitate the investigation of the true incidence of non-O157 VTEC in England and Wales. In this report, we present validation data for the EU-RL VTEC assay (Kagkli et al., 2011) on 545 strains of VTEC from the LGP archive and an evaluation of its application for the detection of VTEC from stool specimens in a prospective study of faecal specimens sent to the LGP for diagnosis of VTEC.
METHODS
Strains of VTEC for validation studies. The 545 strains tested during this study included 169 strains of VTEC O157 submitted by laboratories in England and Wales for confirmation by the LGP in 2010, and 310 non-O157 VTEC strains including well-characterized clinical isolates from pre-2004 and those submitted by reference laboratories in Scotland and Ireland between 2004 and 2010 for serotyping (Table 1 ). In the latter group, the most common O groups were O26 (91), O145 (21), O103 (15), O111 (10) and O113 (6) and these reflect the most important serogroups reported in association with serious illness. This group of strains also included 68 isolates for which the O-antigen was unidentifiable or that were rough. A third set of 66 strains tested were external quality assessment (EQA) and control strains received between 2005 and 2010 as part of a programme of Ring Trials organized among EU Reference Laboratories by the Statens Serum Institut, Copenhagen, and the EU-RL in Rome (Table 1 ). These strains belonged to a wide range of O-groups not necessarily chosen to be representative of clinically important strains but to test identification and PCR testing facilities in participating laboratories. This group contained strains with uncommon vtx gene variants. Control strains for the EU-RL VTEC PCR were H09070 0461 (VTEC O26), which harboured the vtx1 and eae genes, and E32511 (VTEC O157), which harboured vtx2, eae and rfbE O157 genes.
Faecal specimens for prospective clinical evaluation study. A prospective study was carried out between May and October 2011 and included 500 stool samples that were submitted to the reference laboratory for further investigations from patients with HUS, renal failure or bloody diarrhoea and from whom no alternative gastrointestinal pathogen was isolated. Twenty-five of the 500 specimens were from asymptomatic contacts of known VTEC cases.
Bacterial culture of stool specimens. Each stool specimen was streaked directly onto MacConkey agar and Sorbitol MacConkey agar with and without cefixime and tellurite (CT-SMAC and SMAC) and incubated at 37 uC overnight. Immunomagnetic separation was also used for culture-based detection of presumptive VTEC O157 (Chapman et al., 1994) as described in the manufacturer's instructions.
DNA extraction from isolates and faecal specimens. Cultures of VTEC were grown shaken in nutrient broth at 37 uC for 4 h, and a 10 ml sample was diluted in 490 ml distilled water and boiled for 15 min.
DNA was extracted from enrichment cultures of stool specimens. A small loop of faeces was inoculated into modified tryptone soya broth (mTSB) and incubated at 37 uC. After 6 h, and again after overnight incubation, DNA was extracted from mTSB using Instagene (Bio-Rad Catalogue no. 732-6030) (Lesley Allison, Scottish VTEC Reference Laboratory, Edinburgh, personal communication). Briefly, 50 ml enrichment broth was added to 950 ml sterile distilled water and centrifuged at 11 200 g for 1 min. The cell pellet was resuspended in 200 ml Instagene reagent heated at 56 uC for 30 min and boiled for 20 min. Finally, the sample was re-centrifuged as above and the supernatant was removed to a clean tube.
Target detection by PCR and isolation of VTEC from PCRpositive stool specimens. DNA from cultures and faecal extracts was tested by the EU-RL VTEC real-time PCR primers and probes detecting vtx1, vtx2, eae (intimin) and O157rfbE on a Rotorgene Q (Qiagen) in two duplex PCRs ( Table 2 ). The amplification parameters were 95 uC for 5 min, followed by 95 uC for 15 s and 60 uC for 60 s. The cycle threshold was set at 0.05 for all targets except vtx1, for which it was set at 0.025. Faecal inhibition was monitored by adding an internal amplification control -the green fluorescent protein (gfp) gene (Murphy et al., 2007) -to the DNA extract. For all faecal specimens positive for vtx and/or eae (intimin), 10 colonies were picked from either the MacConkey or SMAC plate and retested by the same PCR. If all 10 picks were negative, a further 10 picks were made. Those colonies harbouring the vtx genes were identified biochemically, serotyped and characterized by further PCR assays if needed. This protocol for detection and isolation of VTEC in faeces is referred to below as the HPA Reference Laboratory method.
RESULTS AND DISCUSSION

Validation using pure cultures
All 169 isolates of VTEC O157 tested with the EU-RL VTEC PCR gave concordant results with the block-based PCR for the presence of vtx1 and/or vtx2 genes and eae (intimin) and were also positive for the rfbO157 gene. There was complete agreement in the results of the 310 non-O157 strains regarding the detection of vtx1, vtx2 and eae genes, and none of the non-O157 isolates were positive for rfbO157 (Table 1 ). The results indicated that the EU-RL assay was appropriate for the confirmation of vtx and intimin genes in VTEC O157 and clinically important non-O157 VTEC.
Of 66 EQA strains of serogroups other than O157 tested using the real-time assay, 62 were identified as VTEC (Table 1 ). The four strains not identified possessed the vtx2f subtype; this was not detected by the routine LGP block-based assay but was confirmed by a specific PCR (Schmidt et al., 2000) . These results were expected as generic PCRs generally do not detect vtx2f. Data from the Statens Serum Institut, Copenhagen, on the properties of the EQA isolates showed that the EU-RL assay successfully detected the following subtypes of the vtx1 and vtx2 genes: 1a, 1b, 1c, 1d, 2a, 2b, 2c, 2d, 2e, 2g .
The validation study showed that the EU-RL VTEC PCR was 99.3% sensitive for the detection of vtx genes and only strains harbouring vtx2f genes were not detected. The assay was 100% sensitive and 100% specific for the detection of both the eae and O157 rfbE genes.
Detection of VTEC in stool specimens
During the prospective study, the PCR detected vtx genes in 62 of 500 (12.4%) stool specimens and VTEC was successfully cultured from 36 of the 62 (58%, representing 7.2% of the total samples). Of these 36 cultures, 19 VTEC O157 strains were isolated using the HPA National Standard Methods (i.e. direct plating onto CT-SMAC and SMAC), four VTEC O157 strains were isolated using immunomagnetic separation for E. coli O157 and 13 non-O157 VTEC strains were isolated by following the HPA Reference Laboratory method (i.e. picking 10-20 colonies from MacConkey agar and retesting them with the PCR to identify any VTEC present). The characteristics of these isolates are shown in Table 3 . Nine of the 13 non-O157 isolates were associated with HUS or renal failure and the patients in 11 of the 13 cases had travelled abroad. During the study, a large outbreak of VTEC O104 occurred in Germany (Frank et al., 2011) , and cases from England and Wales that were epidemiologically linked to this outbreak are included in this dataset.
Of the 62 PCR-positive specimens, 36 had C t values in the real-time PCR ranging from 20.1 to 32, and VTEC was recovered from 32 of these by culture; VTEC was isolated from 4 of 27 samples with C t values of 32.1-39.8. Of the 26 patients with specimens that were PCR-positive but culturenegative, 8 had HUS, 3 had acute renal failure, 5 had bloody diarrhoea, 3 had diarrhoea and 7 were asymptomatic contacts of known VTEC cases. No alternative enteric pathogen was isolated from these patients. Clinical symptoms, including HUS, renal failure and bloody diarrhoea, supported a diagnosis of VTEC infection in 16 of the 26 cases. The seven asymptomatic contacts had been exposed to VTEC O157, and low levels of VTEC, undetectable by current culture methods, may have been present in their stool specimens. However, this study demonstrates some of the problems associated with the clinical evaluation of an assay where no equivalent, alternative method is available to confirm the PCR-positive results. Health-care workers may be reluctant to initiate public health interventions and epidemiological investigations on a PCR result alone.
The real-time assay showed a substantial saving in time over the block-based assay (80 min compared to approximately Germany Bloody diarrhoea O104 (5) vtx2
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Brazil HUS/renal failure 5 h), ease of use and reduced risk of contamination. For isolates submitted to the reference laboratory, confirmation of VTEC and indication of the O157 serogroup were available on the day of receipt. The sensitivity and specificity data from the validation study demonstrate the assay to be reliable and robust. Additionally, a real-time PCR-based approach for the detection of VTEC from stool specimens is more sensitive than current methods and would enable frontline diagnostic laboratories to detect all VTEC serogroups, including those other than serogroup O157.
